BioSpace

Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease

Brepocitinib is on a roll. After winning approval for an autoimmune skin disease, Roivant Sciences subsidiary Priovant’s drug hit all primary and secondary endpoints in a pair of Phase 3 non-infectious uveitis trials, leading analysts to say the candidate “looked superior to Humira.”

By BioSpace

1 min read
Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights